These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38971275)

  • 1. Prognostic value of CMTM6 protein in hepatocellular carcinoma involving the regulation of the immune microenvironment.
    Wei Z; Guo X; Li D; Wang J; Lin C; Tan C; Wang Y; Zhu X; Tan S
    Int J Biol Macromol; 2024 Aug; 275(Pt 2):133618. PubMed ID: 38971275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
    Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
    Shang X; Li J; Wang H; Li Z; Lin J; Chen D; Wang H
    Int Immunopharmacol; 2020 Nov; 88():106864. PubMed ID: 32866782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence.
    Muranushi R; Araki K; Yokobori T; Chingunjav B; Hoshino K; Dolgormaa G; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Watanabe A; Kubo N; Harimoto N; Shimoda Y; Sano R; Oyama T; Saeki H; Shirabe K
    Cancer Sci; 2021 Aug; 112(8):3314-3323. PubMed ID: 34080242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma.
    Tan S; Guo X; Bei C; Zhang H; Li D; Zhu X; Tan H
    BMC Cancer; 2022 Aug; 22(1):905. PubMed ID: 35986302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma.
    Yugawa K; Itoh S; Yoshizumi T; Iseda N; Tomiyama T; Morinaga A; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
    Hepatol Commun; 2021 Feb; 5(2):334-348. PubMed ID: 33553979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression.
    Wang H; Gao J; Zhang R; Li M; Peng Z; Wang H
    Int Immunopharmacol; 2020 Jun; 83():106478. PubMed ID: 32278132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma.
    Liu LL; Zhang SW; Chao X; Wang CH; Yang X; Zhang XK; Wen YL; Yun JP; Luo RZ
    Cancer Immunol Immunother; 2021 Feb; 70(2):417-429. PubMed ID: 32770259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autophagy-related CMTM6 promotes glioblastoma progression by activating Wnt/β-catenin pathway and acts as an onco-immunological biomarker.
    Dai L; Xiao J; Li X; Tao Y; Zhou P; Lyu L; Shi Z; Liang X; Jia Z; Jiang S
    J Gene Med; 2024 May; 26(5):e3685. PubMed ID: 38686653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.
    Pang X; Wang SS; Zhang M; Jiang J; Fan HY; Wu JS; Wang HF; Liang XH; Tang YL
    Cancer Immunol Immunother; 2021 Apr; 70(4):1015-1029. PubMed ID: 33104837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGF-β1-Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis Through Transcriptionally Upregulating PD-L1 and CXCL12.
    Chen J; Feng W; Sun M; Huang W; Wang G; Chen X; Yin Y; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
    Gastroenterology; 2024 Jul; 167(2):264-280. PubMed ID: 38417530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CMTM6, a potential immunotherapy target.
    Liang J; Li S; Li W; Rao W; Xu S; Meng H; Zhu F; Zhai D; Cui M; Xu D; Cai J; Zhang B
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):47-56. PubMed ID: 34783871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1.
    Chui NN; Cheu JW; Yuen VW; Chiu DK; Goh CC; Lee D; Zhang MS; Ng IO; Wong CC
    Hepatol Commun; 2022 Jan; 6(1):178-193. PubMed ID: 34558800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer.
    Liu Y; Li X; Zhang H; Zhang M; Wei Y
    Oncogene; 2021 Mar; 40(12):2230-2242. PubMed ID: 33649535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FAT10 induces immune suppression by upregulating PD-L1 expression in hepatocellular carcinoma.
    Wang Q; Tan W; Zhang Z; Chen Q; Xie Z; Yang L; Tang C; Zhuang H; Wang B; Jiang J; Ma X; Wang W; Hua Y; Shang C; Chen Y
    Apoptosis; 2024 Oct; 29(9-10):1529-1545. PubMed ID: 38824477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.
    Ishihara S; Iwasaki T; Kohashi K; Yamada Y; Toda Y; Ito Y; Susuki Y; Kawaguchi K; Takamatsu D; Kawatoko S; Kiyozawa D; Mori T; Kinoshita I; Yamamoto H; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):2003-2011. PubMed ID: 33811537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma.
    Zhang S; Yan Q; Wei S; Feng X; Xue M; Liu L; Cui J; Zhang Y
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Aug; 132(2):202-209. PubMed ID: 34034998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EPDR1 promotes PD-L1 expression and tumor immune evasion by inhibiting TRIM21-dependent ubiquitylation of IkappaB kinase-β.
    Qian X; Cai J; Zhang Y; Shen S; Wang M; Liu S; Meng X; Zhang J; Ye Z; Qiu S; Zhong X; Gao P
    EMBO J; 2024 Oct; 43(19):4248-4273. PubMed ID: 39152265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment.
    Zhang T; Yu H; Dai X; Zhang X
    Front Immunol; 2022; 13():971428. PubMed ID: 35958549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.